In 2020, COVID-19 redefined global health infrastructure, travel norms and daily habits. Today, even though most of the world is back to business as usual, SARS-CoV-2, the virus that triggered a global pandemic still remains silently persistent. With new data emerging in 2025, it's obvious that even if the severity of the virus had reduced for most, its mutation keeps impacting populations in new and complex ways.

Also Read: Can You Take Antibiotics For Covid-19? Here Is What The WHO Says Now

So, what is COVID in 2025 like? From nuanced changes in patterns of symptoms to news on vaccine immunity and AI-driven virus forecasting, here's a closer look at the latest direction of COVID and its continued influence.

While hospitalizations and COVID-19 deaths have significantly slowed from pandemic highs, the virus is hardly gone. In Australia alone, there were 58,000 cases of COVID so far in 2025, though experts say the real numbers are much greater, given decreasing testing and underreporting.

Sentinel surveillance statistics by FluCan, a network of 14 hospitals, reported 781 hospitalizations due to COVID complication in the first quarter of 2025 alone. Another 289 deaths due to respiratory infections caused by COVID happened in the first two months of the year. These statistics point out that, although COVID seems less formidable now, it is still a critical healthcare issue for some sections of the population.

Who Is Still at Risk of Severe COVID?

Currently, the vast majority of individuals who develop COVID have a mild, self-limiting illness. Nonetheless, the following groups are still at risk:

• Older adults, especially those over the age of 70
• Immunocompromised persons, including cancer patients
• Individuals with chronic disease, including diabetes and cardiovascular disease
• Socially disadvantaged populations, including those experiencing homelessness

Social disparities persist to influence health outcomes. In the UK, residents of the most deprived neighborhoods are twice as likely to be admitted to hospital with infectious diseases as those in better-off neighborhoods.

Unique Symptoms of New COVID

The typical COVID symptoms are fever, cough, sore throat, and shortness of breath — remain among the most frequently reported. Yet, newer strains have brought back some distinct symptom trends:

Early in the pandemic, anosmia, or the acute loss of taste or smell, was one of COVID's defining symptoms. The symptom was less frequent with Omicron, but a recent report from a French study indicates a return of anosmia in infections involving the JN.1 variant.

Anosmia is now more variant-specific, so it is a key symptom to monitor for new variants.

One of the key distinguishing factors between COVID and other respiratory diseases such as pneumonia or the flu is the lingering of symptoms, a condition now commonly known as Long COVID.

Scientists at the University of Texas matched patient data between COVID, influenza, and pneumonia. The analysis concluded that symptoms of COVID lasted longer and differed in intensity and nature. Brain fog, breathlessness, and fatigue were the most likely of the symptoms to linger months post-infection. Of interest, these post-viral symptoms appeared more frequently among the unvaccinated.

How Long Does COVID Last in 2025?

For the majority of healthy patients with mild to moderate illness, COVID symptoms disappear in 7 to 10 days. Individuals can, however, be infectious from 48 hours prior to symptom onset until around 10 days after infection.

Notably, symptom duration and recovery vary depending on various factors:

Infection severity: Severe infections may have weeks- or months-long symptoms

Vaccination status: Those who are vaccinated tend to recover more quickly and experience fewer ongoing symptoms

Past history of infection: Future infections are shorter and less symptomatic

A UK study of 5,000 healthcare workers found that fatigue fell progressively with each reinfection — 17.3% after the first, 12.8% after the second, and only 10.8% after the third.

Why Testing Still Matters Even in 2025?

COVID testing continues to be an important tool, particularly in symptomatic people, those with recent contact, or who are high-risk groups. Rapid antigen tests (RATs) are easily accessible, yet a negative RAT is not necessarily conclusive of non-infection — especially in the early phase.

Confirmatory PCR testing is still the gold standard for reliable detection and is advised in individuals who are looking for early medical intervention, particularly in the immunocompromised.

While isolation is no longer required in most areas, public health recommendations include staying home when sick and wearing a well-fitting mask when out in public.

Is Vaccination Still The Most Effective Shield?

COVID vaccines remain effective against severe illness and symptomatic infection. Recent European data (awaiting peer review) indicate that vaccines were 66% effective at preventing symptomatic COVID this winter.

2025 vaccination recommendations are:

Adults 65–74: Boosters every 12 months

Adults 75 and older: Boosters every 6 months

High-risk adults (18+): Eligible for a booster every 6 months

A wide-ranging overview of more than 4,300 studies determined that fully vaccinated individuals were 27% less likely to develop long COVID than unvaccinated individuals.

AI in COVID Testing

As SARS-CoV-2 evolves through mutations, keeping vaccines effective is a moving target. Come forward EVE-Vax, a sophisticated AI system that computer-generates viral proteins that may be able to bypass immune defenses.

Unlike other approaches that respond to current variants, EVE-Vax anticipates ahead of time how the virus could change. By modeling possible future mutations, this technology could transform the way vaccines and treatments are designed — not only for COVID but for other fast-changing viruses such as influenza and HIV.

Is COVID in 2025 Different?

Though the immediate global crisis is over, COVID-19 in 2025 is an evolving public health concern. While the majority of cases are mild, the virus still presents severe threats to at-risk populations, and long-term complications are increasingly understood.

Public health measures now need to walk a tightrope between caution and flexibility — incorporating technological innovation such as AI modeling and continuing global vaccination programs to pre-empt future surges. The virus has evolved, our response must also evolve.

Health authorities in the UK have reported a significant rise in chikungunya cases, a mosquito-borne disease known for causing severe joint pain that can leave sufferers hunched over. Between January and June 2025, there were 73 confirmed cases in England, Wales, and Northern Ireland, more than double the 27 recorded during the same period in 2024. The UK Health Security Agency (UKHSA) says this is the highest number ever recorded, with nearly all linked to overseas travel.

What is Chikungunya?

Spread by the bite of infected Aedes mosquitoes, particularly the Aedes aegypti and Aedes albopictus species, chikungunya is not usually deadly but can be devastating for the very young, the elderly, or those with underlying health conditions.

Typical symptoms include:

• Excruciating joint pain that can leave sufferers bent over in agony
• High fever and headaches
• Muscle aches and swelling in the joints (especially hands and feet)
• Nausea, fatigue, and a rash that’s red, bumpy, and decidedly not Instagrammable

In severe cases, the arthritis-like pain can linger for months or even years, turning every movement into a reminder that mosquitoes are not just a mild holiday nuisance.

The majority of UK cases this year were linked to travel to Sri Lanka, India, and Mauritius. All were reported in England, with London taking the dubious honour of having the most cases. However, the two mosquito species that spread the virus are not established in the UK, so there is no risk of it transmitting locally.

UK logs first cases of oropouche virus

As if one virus was not enough, the UK has also logged its first cases of the oropouche virus, also dubbed ‘sloth fever’. This one circulates in the wild between primates, sloths, and birds before occasionally hopping over to humans via midges or mosquitoes.

Found primarily in the Amazon basin, oropouche has recently started wandering further across the Americas. All the UK cases were linked to travel from Brazil, so unless your staycation involves tree-dwelling mammals and tropical insects, you are safe for now.

The Global Bug Crawl

Chikungunya is typically found in Africa and southern Asia, but 2025 has seen it pop up in unexpected places. Outbreaks have been reported in China, the Indian Ocean islands of Reunion, Mayotte and Mauritius, and across the Americas. In southern China, more than 7,000 people have been infected since June, prompting COVID-style lockdowns in Foshan and at least a dozen other cities in Guangdong province. Hong Kong and Taiwan have also reported cases.

Health officials are urging travellers to take bite prevention seriously.

How to safeguard against mosquito bites

According to the US Centres for Disease Control and Prevention (CDC), your best defence is to stop mosquitoes from making contact in the first place.

Top tips include:

• Use Environmental Protection Agency (EPA)-registered insect repellent
• Wear long-sleeved shirts and trousers (mosquitoes can’t bite what they can’t reach)
• Treat clothing and gear with 0.5% permethrin for extra armour
• Choose accommodation with air conditioning or window screens
• If sleeping outdoors, use a mosquito net unless you enjoy sharing your bed with the local insect population

Vaccination

In addition to covering up and dousing yourself in repellent, some travellers may be advised to get the chikungunya vaccine before heading to certain destinations. Your healthcare provider can help you decide if this applies to your travel plans.

Why the Surge Now?

Several factors could be behind the sharp rise in cases. Increased international travel post-pandemic, changing weather patterns favouring mosquito breeding, and outbreaks in popular holiday destinations have created a perfect storm. Mosquitoes thrive in warm, wet conditions, and with climate change extending those conditions into more regions, these viruses are no longer staying politely within their old borders.

Chikungunya virus can turn a dream getaway into a painful endurance test, and once contracted, it is all about managing symptoms; there is no cure. The same goes for oropouche: prevention is your best friend. In the world of tropical diseases, an ounce of repellent really is worth a pound of cure.

Scott Swift, 73, pop singer Taylor Swift's dad just underwent a quintuple bypass surgery, revealed Taylor during one of the episodes of Travis Kelce and Jason Kelce's New Heights podcast.

She also shared that she had moved in with her dad earlier this year to take care of him for a speedy recovery. She noted that her father has been full of gratitude after the surgery. "He was the loveliest patient ever. He just kept saying thank you over and over again."

Why Did Scott Swift Need A Surgery?

Taylor called the surgery "really intense" and said that her dad's heart always had a healthy ECG or electrocardiogram. He also ensures to get it every year to remain a step ahead of any physical ailments. However, five hard blockages were found in his heart during a resting stress test.

"He's been telling all his friends, 'You need to get the stress test,' because that's what's actually preventative. If you can find that earlier, you don't have to have a bypass surgery," she said.

Taylor confirmed that her father is doing "incredibly well" and that his humor has helped him go through during the hard times. It still is very much intact in him.

She shares that he did not know how many blockages he's had, on being told that he underwent a quintuple bypass, which means five blockages, he also joked about it. "Well, you see, I come from a very competitive family," he told Taylor.

What Is A Stress Test?

As per the National Institute of Health (NIH), US, it is a form of physical test that typically utilizes electrocardiography along with blood pressure monitoring and exercise, which involves a treadmill or bicycle.

However, in a resting stress test, the assessment happens when the heart muscle is at rest after stress. This stress helps in identifying areas of reduced blood flow like ischemia or damage to the heart muscle, which can indicate conditions like coronary artery disease.

The test involves injecting a radioactive tracer into the bloodstream, then using a special camera to take images of the heart at rest and after stress.

What Is A Bypass Surgery?

As per Johns Hopkins Medicine, bypass surgery or coronary artery bypass graft surgery (CABG) is a procedure used to treat coronary artery disease. Coronary artery disease (CAD) is the narrowing of the coronary arteries. These are the blood vessels that supply oxygen and nutrients to the heart muscle. CAD is caused by a build-up of fatty material within the walls of the arteries. This buildup narrows the inside of the arteries, limiting the supply of oxygen-rich blood to the heart muscle.

How Does It Work?

One way to treat the blocked or narrowed arteries is to bypass the blocked portion of the coronary artery with a piece of a healthy blood vessel from elsewhere in your body. Blood vessels, or grafts, used for the bypass procedure may be pieces of a vein from your leg or an artery in your chest. An artery from your wrist may also be used.

ALSO READ: 4 Rare Heart Diseases That Are Becoming Common By Each Passing Day

This surgery is done to treat a blockage or narrowing of one or more of the coronary arteries. It can restore the blood supply to your heart muscle when nonsurgical procedures are not a choice.

More Updates From The Swift Family

In addition to Scott, Taylor shared that her mom Andrea Swift, too, under a procedure. “My mom just got a new knee,” Taylor shared. “She’s doing great. She’s scampering around. We’re not quite at scampering yet, but she’s doing great.”

She noted that her parents are her best friends.

"It was actually one of the most special things that's ever happened to me, spending all that time with them this summer. You have those long talks that you don't have when it's a small, concentrated period of time.”

The U.S. Food and Drug Administration (FDA) has announced that the nationwide shortage of sodium chloride 0.9 percent intravenous (IV) saline solution, which is a critical medical supply used in hospitals and emergency care, has officially come to an end. The resolution marks a significant milestone in stabilizing the supply of one of the most essential tools in patient care.

Collaborative Effort to Restore Supply

FDA Commissioner Marty Makary, M.D., M.P.H., credited the resolution of the shortage to a coordinated effort between the FDA, the Administration for Strategic Preparedness and Response (ASPR), and industry partners. According to Makary, this multi-agency and cross-sector collaboration allowed for rapid action to address the supply gap that had strained healthcare facilities across the country.

To overcome the shortage, the FDA and its partners implemented several urgent measures. These included enabling the temporary import of IV saline solutions from approved international sources, expediting the review process for domestic manufacturing expansions, and extending expiry dates for existing products after rigorous safety assessments. This combination of strategies helped boost production capacity and prevent supply chain bottlenecks.

Impact on Hospitals and Patient Care

Sodium chloride 0.9 percent IV saline is used for hydration, administering medications, and treating dehydration and other critical conditions. The shortage, which had persisted for months, forced hospitals to ration supplies and find alternative solutions. Medical professionals often had to adjust treatment protocols or use smaller IV bags to stretch resources, a situation that placed additional strain on already burdened healthcare systems.

Now, with supplies back to normal levels, the FDA has confirmed that the product will be removed from its official Drug Shortage Database. Facilities are being advised to return to using FDA-approved products whenever available.

ALSO READ: The Truth About IV Drips: Are They Better Than Food Or Supplements?

Ongoing Efforts to Prevent Future Shortages

While celebrating the resolution, the FDA emphasized that its work to secure medical product availability is far from over. Makary stressed that the agency remains committed to addressing other ongoing shortages, including those affecting certain IV fluids.

“The FDA remains focused on doing all we can to help mitigate shortages and prevent them from occurring,” Makary said in a statement. “We will continue working diligently to monitor supply levels, anticipate potential disruptions, and support a robust, secure, and transparent supply chain for medical products.”

The agency’s strategy involves close monitoring of manufacturer reports, collaboration with other federal agencies, and engagement with the private sector to anticipate challenges before they escalate into full-scale shortages.

A Model for Crisis Response

Experts say the resolution of the saline shortage could serve as a model for responding to future disruptions in medical supply chains. By acting quickly, coordinating with multiple stakeholders, and making temporary regulatory adjustments, the FDA and its partners were able to restore availability without compromising patient safety.

Public health advocates note that the success also underscores the importance of maintaining diverse manufacturing sources, both domestically and internationally, to safeguard against sudden disruptions caused by disasters, supply chain issues, or unexpected surges in demand.

The FDA’s announcement brings relief to healthcare providers nationwide, who have been navigating supply constraints for essential items over the past few years. With IV saline now in stable supply, hospitals can focus more on patient care without the added stress of product scarcity.

However, the agency cautions that vigilance is essential. The FDA will continue to work with manufacturers, monitor production levels, and apply lessons learned from this shortage to strengthen the overall resilience of the nation’s medical supply system.